Best to scroll back on the threads and have a look at Wilsons...

Best to scroll back on the threads and have a look at Wilsons very thorough report for their derisked near $2 sp by years end. Other broker reports more conservative sp but they were all predicted before sereptas fail. The barometer now leans into the derisked price rather than risked because of this shift we've been discussing away from gene therepy.

investors might be cautious around what our funding might look like. Our sp so so low right now, if a partner is announced theres still enough time to get in and buy low.

our future sp has a lot to do with how we manage funding for ph 2b/3 trial. That will be announced in a few months max, and could give us 30c up to a dollar. Or a possible TO some suggesting beyond $2.